サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：抗核抗体検査の世界市場（2022年～2029年）
市場調査レポート
商品コード
1074115

抗核抗体検査の世界市場（2022年～2029年）

Global Antinuclear Antibody Test Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗核抗体検査の世界市場（2022年～2029年）
出版日: 2022年05月07日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の抗核抗体検査市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界の抗核抗体検査市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の抗核抗体検査市場－市場の定義と概要

第3章 世界の抗核抗体検査市場－エグゼクティブサマリー

  • 市場の内訳：製品別
  • 市場の内訳：技術別
  • 市場の内訳：疾患別
  • 市場の内訳：エンドユーザー別
  • 市場の内訳：地域別

第4章 世界の抗核抗体検査市場－市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の抗核抗体検査市場－業界分析

  • サプライチェーン分析
  • 価格分析
  • アンメットニーズ

第6章 世界の抗核抗体検査市場－COVID-19分析

  • 市場のCOVID-19分析
    • COVID-19以前の市場シナリオ
    • 現在のCOVID-19の市場シナリオ
    • COVID-19以後の市場シナリオ/将来の市場シナリオ
  • COVID-19における価格の力学
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の抗核抗体検査市場：製品別

  • イントロダクション
    • 市場規模分析、および前年比成長分析（％）：製品別
    • 市場魅力指数：製品別
  • 試薬およびアッセイキット*
    • イントロダクション
    • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
  • システム
  • ソフトウェア
  • サービス

第8章 世界の抗核抗体検査市場：技術別

  • イントロダクション
    • 市場規模分析、および前年比成長分析（％）：技術別
    • 市場魅力指数：技術別
  • 蛍光抗体法*
    • イントロダクション
    • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
  • ELISA
  • マルチプレックスアッセイ

第9章 世界の抗核抗体検査市場：疾患別

  • イントロダクション
    • 市場規模分析、および前年比成長分析（％）：疾患別
    • 市場魅力指数：疾患別
  • 関節リウマチ*
    • イントロダクション
    • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
  • 全身性エリテマトーデス
  • その他

第10章 世界の抗核抗体検査市場：エンドユーザー別

  • イントロダクション
    • 市場規模分析、および前年比成長分析（％）：エンドユーザー別
    • 市場魅力指数：エンドユーザー別
  • 病院*
    • イントロダクション
    • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）
  • 臨床ラボ
  • その他

第11章 世界の抗核抗体検査市場：地域別

  • イントロダクション
    • 市場規模分析、100万米ドル（2020年～2029年）、および前年比成長分析（％）（2021年～2029年）：地域別
    • 市場魅力指数：地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東とアフリカ

第12章 世界の抗核抗体検査市場－競合情勢

  • 主な開発と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業のリスト

第13章 世界の抗核抗体検査市場－企業プロファイル概要

  • Abbott Laboratories(Alere Inc)*
    • 企業概要
    • 製品ポートフォリオおよび説明
    • 主要ハイライト
    • 財務概要
  • BioVision Inc
  • Antibodies Incorporated
  • PerkinElmer Inc
  • Zeus Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Inova Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech plc.
  • Immuno Concepts

第14章 世界の抗核抗体検査市場－DataM

  • 付録
  • 当社・アプリケーションについて
  • 問い合わせ先
目次
Product Code: DMMD4898

Market Overview

The global antinuclear antibody test market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

The anti-nuclear antibody test (ANA) or FANA (fluorescent anti-nuclear antibody) is a blood test that detects the presence of auto-antibodies in the serum, which are antibodies produced by the body against its cells. The human immune system recognizes foreign things such as bacteria, viruses, fungus, and other microbes in normal circumstances and mounts an immune response against them. Many antibodies are produced during this immune reaction, which binds and kills any foreign particles in the body.

Market Dynamics

Technological advancements and increased R&D funding for new products are expected to drive market growth.

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) established a classification criterion for systemic lupus erythematosus (SLE) in 2019, which suggested that immunofluorescence testing on solid-phase anti-nuclear antibody screening immunoassay and HEp-2 cells with equal performance was highly preferred. Moreover, the market for anti-nuclear antibody testing is growing due to government healthcare insurance, an increase in autoimmune disorders awareness campaigns, and reimbursement regulations. For instance, The World Lupus Federation (WLF) collaborates with roughly 250 lupus organizations from 75 countries across six continents to assist lupus patients. WLF works to improve public awareness about Lupus and provide better healthcare for those who suffer from the disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

However, there are rigorous requirements for medical device clearance in developing economies and the demand of large resources to purchase high-priced equipment, a scarcity of competent medical personnel, and a lack of awareness of the disease and effective treatment. Thus, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The impact of the SARS-CoV-2 pandemic on people with arthritis has been addressed, although evidence on other rheumatic disorders, such as systemic lupus erythematosus (SLE), is rare. Thromboembolism, an imbalanced type I interferon response, and complement activation are all concerns associated with severe SARS-CoV-2 infection, just as they are with SLE. SARS-CoV-2 antibodies were evaluated and compared with SLE development and antinuclear antibody (ANA) levels in longitudinal samples taken before immunization. As a result, dependable SARS-CoV-2 antibody assays are in high demand and critical for reopening societies following lockdowns and allowing travel. Furthermore, as COVID-19 immunization programs spread worldwide, the need for reliable SARS-CoV-2 antibody assays (to confirm a successful vaccine response) will almost certainly persist in the coming years.

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Reagents & Assay Kits segment is expected to hold the largest market share in antinuclear antibody test market

The reagents & assay kits segment is expected to dominate in 2020. The segment's growth benefits because high adoption in the clinical and scientific fields and the development of standardized procedures aid in producing reliable and repeatable outcomes. High efficiency and lower prices increase the number of reagent/assay rental agreements are some of the factors the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global antinuclear antibody test market

In 2020, North America accounted for the highest revenue share. The rising geriatric population, increasing prevalence of autoimmune diseases, growing population and healthcare spending, and an increase in the number of people covered by medical insurance in the United States are factors that the market is expected to boost in the region in the forecast period. For instance, In the United States, autoimmune illnesses are the third most prevalent cause of chronic illness. Although many autoimmune disorders are uncommon, the National Institutes of Health (NIH) estimates that they affect between 5% and 8% of the population in the United States. Autoimmune illnesses are becoming more common for unclear reasons.

Moreover, According to the American Autoimmune Related Diseases Association (AARDA), up to 50 million Americans have an autoimmune disease, costing $86 billion every year. According to the United States Department of Health and Human Services (HHS), these disorders are the fourth greatest cause of disability in women in the United States and the eighth top cause of mortality among women aged 15 to 64. Therefore, it has increased the demand for antinuclear antibody tests in the region. Thus, the North American region is expected to boost in the forecast period from the above statements.

Competitive Landscape

Major key players in the antinuclear antibody test market are Abbott Laboratories (Alere Inc), BioVision Inc, Antibodies Incorporated, PerkinElmer Inc, Zeus Scientific, Inc., Bio-Rad Laboratories, Inc., Inova Diagnostics, Thermo Fisher Scientific, Inc., Trinity Biotech plc. and Immuno Concepts.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

­Product Portfolio:

Thermo Scientific Accutex Systemic Lupus Erythematosus (SLE) Latex: It is a competitively priced qualitative and semi-quantitative serological test for the detection of antinuclear antibodies in serum or plasma as an aid in the diagnosis of systemic lupus erythematosus.

Why Purchase the Report?

Visualize the composition of the antinuclear antibody test market segmentation by product, technique, disease, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in Antinuclear antibody test market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of antinuclear antibody test market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global antinuclear antibody test market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Global Antinuclear Antibody Test Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Antinuclear Antibody Test Market - Market Definition and Overview

3. Global Antinuclear Antibody Test Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Technique
  • 3.3. Market Snippet by Disease
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Antinuclear Antibody Test Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements and increased R&D funding for new products are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of the disease and effective treatment are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Antinuclear Antibody Test Market - Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. Global Antinuclear Antibody Test Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Antinuclear Antibody Test Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product Segment
  • 7.2. Reagents & Assay Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Systems
  • 7.4. Software
  • 7.5. Services

8. Global Antinuclear Antibody Test Market - By Technique

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Sample
    • 8.1.2. Market Attractiveness Index, By Type of Sample Segment
  • 8.2. Immunofluorescence*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. ELISA
  • 8.4. Multiplex Assay

9. Global Antinuclear Antibody Test Market - By Disease

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 9.1.2. Market Attractiveness Index, By Disease Segment
  • 9.2. Rheumatoid Arthritis*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Systemic Lupus Erythematosus
  • 9.4. Others

10. Global Antinuclear Antibody Test Market - By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinical Laboratories
  • 10.4. Others

11. Global Antinuclear Antibody Test Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technique
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Antinuclear Antibody Test Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Antinuclear Antibody Test Market- Company Profiles

  • 13.1. Abbott Laboratories (Alere Inc)*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. BioVision Inc
  • 13.3. Antibodies Incorporated
  • 13.4. PerkinElmer Inc
  • 13.5. Zeus Scientific, Inc.
  • 13.6. Bio-Rad Laboratories, Inc.
  • 13.7. Inova Diagnostics
  • 13.8. Thermo Fisher Scientific, Inc.
  • 13.9. Trinity Biotech plc.
  • 13.10. Immuno Concepts

LIST NOT EXHAUSTIVE

14. Global Antinuclear Antibody Test Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us